Tryton Announces Launch in Several European and Eastern European Countries

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to
definitively treat bifurcation lesions, today announced that the company
has launched the Tryton Stent System in Switzerland, Sweden, Finland,
Turkey, Hungary, Czech Republic, Slovakia and Latvia.

“We are pleased to expand availability of the Tryton Stent System to
additional countries in Europe and Eastern Europe, broadening our reach
and bringing the Tryton solution to many more patients and clinicians,”
said J. Greg Davis, president and CEO of Tryton Medical.

“I have been very pleased with my experience with the Tryton Stent,
which provides a simple solution to a highly complex clinical problem,”
said Imre Ungi, M.D., Ph.D., associate professor and director of
Invasive Cardiology Division, Department of Cardiology at the University
of Szeged in Hungary.

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. Tryton’s highly deliverable cobalt chromium stent
is deployed in the side branch artery using a standard single-wire
balloon-expandable stent delivery system. A conventional drugeluting
stent is then placed in the main vessel.

Excellent Six-Month Clinical Results

The Tryton Side Branch Stent System demonstrated excellent six-month
clinical and angiographic results in a first-in-man study of the system
and excellent six-month clinical results from almost 200 patients in
four different registries with a rate of target lesion revascularization
of less than four percent.

The stent system has received CE Mark approval in Europe and is
commercially available in 21 countries throughout Europe and the Middle
East. It is not approved in the United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The
company was founded in 2003 by Aaron V. Kaplan, M.D. (Professor of
Medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center)
and Dan Cole to develop stents for the definitive treatment of
bifurcation lesions. The Tryton Side Branch Stent System, approved for
sale in Europe, is designed to offer a dedicated strategy for treating
these challenging cases. Privately held, Tryton is backed by Arnerich
Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest
Ventures. For more information please visit trytonmedical.com.